This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about E3 ubiquitin-protein ligase parkin.
Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPT5, TOMM20, USP30, ZNF746 and AIMP2 (PubMed:10973942, PubMed:10888878, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:16135753, PubMed:21376232, PubMed:23754282, PubMed:23620051, PubMed:24660806, PubMed:24751536).
Mediates monoubiquitination and'Lys-6','Lys-11','Lys-48'-connected and'Lys-63'-linked polyubiquitination of substrates depending on the circumstance (PubMed:19229105, PubMed:20889974, PubMed:25621951).Participates in the elimination and/or detox of abnormally folded or damaged protein by mediating'Lys-63'-linked polyubiquitination of misfolded proteins like PARK7:'Lys-63'- linked polyubiquitinated misfolded proteins are then recognized by HDAC6, resulting in their recruitment to aggresomes, followed by degradation (PubMed:17846173, PubMed:19229105). Mediates'Lys-63'- linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation (PubMed:11590439, PubMed:11431533, PubMed:19229105, PubMed:11590439, PubMed:15728840).
Human | |
---|---|
Gene Name: | PRKN |
Uniprot: | O60260 |
Entrez: | 5071 |
Belongs to: |
---|
RBR family |
AR-JP; E3 ubiquitin ligase; E3 ubiquitin-protein ligase parkin; EC 6.3.2.-; LPRS2; PARK2; parkin 2; Parkin; Parkinson disease protein 2; Parkinson juvenile disease protein 2; parkinson protein 2, E3 ubiquitin protein ligase (parkin); PDJ; PDJjuvenile) 2, parkin; PRKN
Mass (kDA):
51.641 kDA
Human | |
---|---|
Location: | 6q26 |
Sequence: | 6; NC_000006.12 (161347417..162727802, complement) |
Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum (at protein level).
Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Mainly localizes in the cytosol. Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Mitochondrial localization gradually increases with cellular growth. Also relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent.
In this article, we will discuss Boster Bio's Anti-Parkin/PRKN Antibody PicoBand(tm) and the benefits of using the PRKN marker. We'll also discuss the use of the Boster Bio PRKN Marker and provide some troubleshooting tips for users. For further reading, please visit BosterBio.com.
Developed using the renowned reagent dilution method, the Boster Bio Anti-Parkin/PRKN Antibodies are a perfect complement to your research. Suitable for Western Blot, ICC, and IHC applications, the antibodies are tested and validated for a variety of applications. These include studies in human, mouse, and rat cells.
If you're unable to achieve the desired staining results using Boster Bio's PRKN Marker, you might not be sure what to do. The following guide provides immunohistochemistry troubleshooting tips, including common problems such as weak staining and high background. Moreover, the guide provides useful optimization tips for optimal results. The guide also includes a comprehensive list of resources for immunohistochemistry. In addition, it includes key protocols and techniques.
PMID: 9560156 by Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
PMID: 19501131 by Kasap M., et al. Evidence for the presence of full-length PARK2 mRNA and Parkin protein in human blood.